Our Focus
We are leveraging our global R&D capabilities to develop innovative cell therapies targeting cancer and inflammatory & immunological diseases
Innovative T Cell Therapeutic Modalities for Multiple Diseases
Our focused therapeutic areas are following:
Hematologic Malignancies
Solid Tumors
Inflammatory & Immunological Diseases
We partner with, and license to, multinational pharmaceutical companies to facilitate the commercialization of our products to maximize worldwide patient accessibility.
"AbelZeta is committed to developing and bringing to market proprietary immune cell therapies for the treatment of cancerous diseases and serious inflammatory and immunological conditions."
CELL THERAPEUTIC PLATFORMS
CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) MONO-/BI-SPECIFIC/ARMORED
CAR-T is a type of immunotherapy that harnesses the body’s immune system, whereby a patient’s own T-cells (a type of white blood cell) are modified to recognize and attack cancer cells, as well as inflammation. Moreover, CAR-T therapeutics can be designed to target specific cancer cells based on the proteins they express, potentially reducing damage to healthy cells.
TUMOR-INFILTRATING LYMPHOCYTES (TIL)
TIL is another innovative approach in cancer treatment that, like CAR-T, is also an immunotherapy. Tumor-infiltrating lymphocytes are white blood cells that have migrated from the bloodstream into a tumor. Their presence often indicates an immune response against the tumor. TIL therapy involves extracting these lymphocytes, expanding them outside the body, and then reintroducing them to the patient to combat the tumor.
